Sigachi Laboratories: Financial Results for FY24

08 November 2024

• Revenue- In FY24, the company's revenue grew by 5%, rising from Rs. 1.29 cr  in FY23 to Rs. 1.35 cr, primarily driven by increased revenue from bulk drugs, intermediaries, and lease rentals. Additionally, net income increased by 51%, from Rs. 1.31 cr in FY23 to Rs. 1.97 cr in FY24, resulting in a 51% rise in EPS, which climbed from Rs. 1.94 in FY23 to Rs. 2.92 in FY24.
• Financial Position- The company's total assets expanded by 20%, increasing from Rs. 31.26 cr in FY23 to Rs. 37.34 cr in FY24. Likewise, total equity rose by 17%, going from Rs. 30.74 cr in FY23 to Rs. 36.01 cr in FY24.